InvestorsHub Logo
Followers 1880
Posts 137587
Boards Moderated 5
Alias Born 01/03/2007

Re: None

Monday, 01/05/2015 8:26:51 AM

Monday, January 05, 2015 8:26:51 AM

Post# of 242
Regeneron upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Regeneron to Overweight with a $485 price target following recent survey results that indicates robust DME penetration for Elea. The analyst raised its Eylea 2015 estimate to 2.4B and 2016 to $2.7B and sees additional catalysts from further dupilumab data and Eylea ang2/PDGF combo data, and alirocumab approvals

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent REGN News